摘要
目的：皮肤慢性溃疡是临床常见的难治性疾病,病程迁延反复,给患者带来巨大的生理和心理痛苦,目前其愈合机制尚未完全清楚,治疗也颇为棘手。本研究旨在通过皮肤慢性溃疡的实验室与临床研究,从分子生物学水平探索皮肤慢性溃疡的愈合机制,进一步探求中药治疗该病的作用靶点,用客观的数据证实蜚蠊提取液治疗皮肤慢性溃疡的有效性,为寻求有效、方便、价廉的治疗方案提供实验室依据和研究数据支持。
方法：把符合纳入标准的皮肤慢性溃疡患者68人随机分为治疗组33人,对照组35人。如有合感染的病人可全身抗感染治疗,如合并糖尿病患者可以同时采用降糖药物。二组均用生理盐水棉球将创面清洗干净,用干棉球拭干,治疗组用蜚蠊提取液(康复新液)湿敷,对照组将生肌散“飞”到溃疡面上,然后用无菌纱布包扎。二组均每日更换敷料1次,治疗4周。观察皮损愈合情况和治愈率。治疗前后取皮损病理切片,用免疫组化法检测皮损的Smad3基因表达水平、TGF-01和VEGF表达水平。
结果：治疗前,试验组和对照组皮损面积、溃疡色泽积分、分泌物积分、自觉疼痛程度积分、皮损的气味积分、空腹血糖水平组间对比无明显差异(P>0.05),具有可比性；治疗1、2、3、4周后,试验组与对照组皮损面积无明显差异(P>0.05)；试验组和对照组病例溃疡面分泌物积分均无明显差异(P>0.05)；试验组和对照组病例溃疡面气味积分均无明显差异(P>0.05)；试验组病例空腹血糖水平低于6.1mmol/L、6.1～11.1mmol/L.高于11.1mmol/L的例数分别是21例、8例、5例,对照组分别是23例、6例、5例,试验组和对照组空腹血糖水平分组对照无明显差异,(P<0.05)；试验组痊愈率、显效率、好转率和无效率分别是分别是8.82%、29.41%、47.06%、14.71%,对照组的痊愈率、显效率、好转率和无效率分别是14.71%、26.47%、47.06%、11.76%,治疗4周后,试验组患者痊愈率明显低于对照组,(P<0.05),显效率、好转率和无效率均无明显差异,具有可比性,(P>0.05)；治疗第1周和第2周,试验组和对照组病例溃疡色泽积分无明显差异(P>0.05),治疗第3周和第4周,试验组病例溃疡色泽积分明显低于对照组,(P<0.05),治疗1周、2周、3周后,试验组和对照组病例自觉疼痛程度无明显差异(P>0.05),治疗4周后,试验组病例自觉疼痛程度明显小于对照组(P<0.05)；试验组病例中长期卧床或行动受限者、伴发糖尿病者、伴发静脉曲张者、外伤诱发者、放射线照射者分别是3例、13例、17例、21例、2例,试验组分别是4例、11例、18例、25例、2例,试验组和对照组组间数据对比无显著差异,具有可比性,(P>0.05)；试验组病例中出现用药后疼痛、瘙痒者分别是1例、2例,对照组分别是2例、2例；试验组和对照组病例中,以41-50岁和51～60岁的最多,一共占到总例数的60%左右。治疗前,实验组Smad3基因、TGF-β1、VEGF表达阳性细胞数比例是79.62±5.26%、29.74±3.12%、21.65±3.12%,对照组阳性细胞数比例分别是78.32±4.97%、29.13±3.98%、22.44±3.11%,治疗4周后,实验组Smad3基因、TGF-β1、VEGF表达阳性细胞数比例分别是18.85±1.88%、79.07±7.80%、59.24±3.74%；对照组阳性细胞数比例分别是20.03±2.42%、77.47±7.68%、61.09±4.10%,实验组和对照组皮损病理切片Smad3基因、TGF-β1、VEGF表达水平无明显差异,具有可比性(P>0.05)；治疗4周后,实验组切片Smad3基因表达水平低于对照组,TGF-β1、VEGF表达阳性细胞数比例高于对照组,但是不具有统计学意义(P>0.05)；治疗前后对照,实验组Smad3基因表达水平显著下降,(P<0.05),TGF-β1、UVEGF表达水平明显升高(P<0.05)。
结论：1.蜚蠊提取液有促进创面愈合的作用,临床疗效与对照组相当。治疗后试验组和对照组的皮损面积,分泌物积分,气味积分,显效率、好转率和无效率没有明显差异；试验组皮损色泽积分、自觉疼痛程度积分、痊愈率三项指标临床疗效优于对照组；试验组和对照组分别有3例、4例病例出现用药后疼痛、瘙痒；试验组和对照组病例中,以41-50岁和51-60岁的最多,一共占到总例数的60%左右；蜚蠊提取液用于治疗皮肤慢性溃疡具有有效性、安全性。2.蜚蠊提取液可能是通过下调Smad3基因表达水平,同时TGF-β1、VEGF的生成和游走,促进创面毛细血管再生、肉芽组织新生,从而加快皮肤慢性溃疡创面愈合。
Objective:chronic skin ulcer is a common. refractory disease with long course.it makes patients suffer great physical and psychotogical pain.At present, its difficult to heal the chronic skin ulcer,and the healing mechanism is not completely clear. This research aims to explore the mechanism of healing of chronic ulcer of skin from the level of molecular biology by laboratory and clinical research on the chronic skin ulcer.To further explore the working target of Chinese medicine treatm-
ent, meanwhile,to confirm the effectiveness of cockroachextract liquid in treatment of chronic skin ulcer with objective data. The ultimate aim is to provide laboratory basis and data support for seeking the effective、convenient and inexpensive treatment of chronic skin ulcer.
Methods:68sufferers who meet the inclusion criteria of chronic skin ulcer were randomly divided into experimental group and control group. the Infected patients should be given anti-infection treatment, the patients with diabetesmellit-us can also take hypoglycemic agents. clean the ulcer with physiological saline cotton, then wipe the ulcer with dry cotton, the experimental group sufferers were treated with cockroach extract liquid wet compress(Kangfuxin liquid),while spread the Shengjisan over the ulcer surface of control group sufferers, finally bandaged ulcer the with sterile gauze. The two groups were changed dressing everyday, for4weeks. To observe the healing course and cure rate. Before and after the treatment, took the skin lesions tissue samples of the two groups,the expression of Smad3gene、TGF-β1and VEGF was examined by immunohistochemistry method.
Results:Before treatment, the skin lesion area、the score of Secretion、the score of skin lesions clour、the score of skin lesions odor、the score of soreness and asting plasma glucose level of both experimental group and control group were comparable,with no significant difference (P>0.05);After1,2,3,4weeks of treatment, the skin lesion area、the score of secretion、the score of skin lesions clour of both experimental group and control group were comparable,with no significant difference (P>0.05);After1,2weeks of treatment, the score of skin lesions clour of both experimental group and control group were comparable,with no significant difference(P>0.05), After3,4weeks of treatment, the score of skin lesions clour of experimental group were significantly lower than the control group date(P<0.05);t After1,2,3weeks of treatment, the score of soreness of both experimental group and control group were comparable,with no significant difference(P>0.05), After4weeks of treatment, the score of soreness of experimental group were obviously lower than the control group date (P<0.05);the cure rate. success rate、better rate and the rate of Inefficiency was8.82%、29.41%、47.06%and14.71%respectively；while the date for the control group was14.71%、26.47%、47.06%and11.76%respectively; for experimental group,the number of patients whose asting plasma glucose level below6.11umol/ml、between6.12and11.1umol/ml、 above11.2umol/ml was21、8and5,while the result of control group was23、6and5;for experimental group;the number of patients who had suffered bedridden or disabled in action、diabetes、varicose vein of lower limb、skin injure or radiation was3、13、3、7、21、2, while the number of control group patients was4、11、18、252; because of the cockroach extract liquid wet compress (Kangfuxin liquid),the patients who suffered pain or itching was1and2,because of theShengjisan,the patients who suffered pain or itching was2and2;for the patients of both experimental group and control group,about60%of them was between41～50years old and between51～60years old.Before treatment, for the experimental group,the percentage of Smad3gene、TGF-β1and VEGF was79.62±5.26%、29.74±3.12%、21.65±3.12%; for the control group, the the percentage of Smad3gene、TGF-β1and VEGF expressed positive cells was78.32±4.97%、29.13±3.98%、22.44±3.11%、 After4weeks of treatment, for the experimental group,the Smad3gene、TGF-β1and VEGF was18.85±1.88%、79.07±7.80%、59.24±3.74.%；for the control group, the date was20.03±2.42%,77.47±7.68%、61.09±4.10%. Before treatment,the expressed positive cells of Smad3gene、TGF-β1and VEGF in both experimental group and control group were comparable,with no significant difference (P>0.05);after the treatment for4weeks,the expressed positive cells of Smad3gene in experimental group is fewer than the control group obviously (P<0.05),while the TGF-β1and VEGF were more than control group obviously (P<0.05);when Completed the experiment,the expressed positive cells of Smad3gene reduce, and the expressed positive cells of TGF-β1and VEGF increased obviously (P<0.05).
Conclusion:1. cockroach extract liquid can promote wound healing, clinical curative effect of cockroach extract liquid was similar to that of control group; after treatment, the skin lesion area、the score of Secretion、the score of skin lesions odor、success rate、better rate and the rate of Inefficiency of both experimental group and control group has no obvious difference; three indicators of clinical curative effect including the score of skin lesions soreness. the score of skin lesions clour and the cure rate of experimental group is better than the control group; the asting plasma glucose level and medical history analysis of the two groups has no obvious difference;3cases in experimental group and4cases in control group complainof pain or itching after treatment;In cases of the experimental group and control group, the cases who were41to50years old and up to51-60years old were accounted for about60%of the total. The treatment of cockroach extract liquid for chronic skin ulcer is effective, safe.2.cockroach extract liquid probably inhibit the expression of Smad3gene, meanwhile,promote the TGF-β1, VEGF generation and migration, promote newborn of ulcer granulation tissue and regeneration of capillary, thus speed up the chronic skin ulcer healing.
引文
【1】王一飞,李欣,李斌.中医药促进创面修复的细胞与分子生物学机制[J].中国中西医结合杂志.2012,32(6)：860-862
[2]Corral CJ,Siddiqui A,Wu L,et al.Vascular endothelial growth factor is more important than basic fibroblastic growth factor du-ring ischemic wound healing[J].ArchSurg,1999,134(2):200-205
【3】蔡源源,李光早.VEGF的调控及其作用研究进展[J].组织工程与重建外科杂志,2011,7(1)：51-55
[4]Stroschein SL,Wang W,Luo K.Cooperative binding of smad proteins to two adjacent DNA elements in the plasminogen aclivator inhibitor 1 promoter mediates transforming growth factor beta induced smad dependent transcriptional activeation [J].J Biol Chem,1999,274(14):9431-9441
【5】姜文锋,徐功利.肿瘤细胞耐药表型及其机制的研究进展[J].山东医药,2001,41(5)：56-57
【6】现代创伤修复学[M]／付小兵,王德文主编.-北京：人民军医出版社,1999：374
【7】陈伟,付小兵,孙同柱等.增生性瘢痕组织TGF-β异构体与受体含量变化及对瘢痕形成的影响[J].中国修复重建外科杂志,2000,16(4)：252
[8]Ashcroft GS,MassagueJ,Blain SW.Lo RS.TGF-beta signa-ling in growth control.cancer, and heritable disorders[J]. Cell, 2000,103(2):295-309
[9]Datto MB, Frederick JP, Pan L, et al.Targeted disruption of Smad3 reveals an essential role in transforming growth factor β mediated signal transduction.Mol Cell Biol1999,19:2495-2504
【10】邸艳飞,朱旭东,刘琛等.大鼠皮肤伤口愈合中TGFβ信号转导分子Smad3、Smad4的表达[J].中华创伤杂志,2002,1(87)：407～409
[11]Nakao A.Afrakhte M.Moren A.et al.Identification of Sma-d7,TGF-β inducible antagonist of TGF-signalin[J].Nature,1997, 389:631-35
[12]Hayashi H,Abdollah S.Qiu Y,et al.The MAD-related prot-ein Smad7 associates with the TGF-βreceptor and functions as an antagonist of TGF-βsignaling[J].Cell,1997,89:1165-1173
[13]Heldin CH.Miyazono K,Dijeke PT.TGF-βsignaling from c-ell membrane to nucleus through SMAD proteins[J]. Nature, 1997,390:465-471
【14】王正国.创伤修复的分子生物学研究[J].中华创伤杂志,2000,16(6)：326
[15]Ashcroft GS,MassagueJ,Blain SW,Lo RS.TGF-beta sign-aling in growth control,cancer,and heritable disorders[J]. Cell, 2000,103(2):295-309
[16]Ashcroft GS,MassagueJ,Blain SW,Lo RS.TGF-beta sign-aling in growth control,cancer,and heritable disorders Cell[J], 2000,103(2):295-309
[17]Jalali S，del Pozo MA.Chen K,et al.Integrin-mediated mec-hanotransduction requires its dynamic interaction with specific extracellular matrix(ECM)ligands[J].Proc Natl Acad Sci USA, 2001,98(3):1042-1046
[18]Carmeliet P.Angiogenesis in life,disease andmedicine[J]. Nature,2005,438(7070):932-936
[19]Lebherz C,von Degenfeld G,Karl A,et al.Therapeutic ang-logenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factorretroinfusi on[J] Endothelium,2003,10(4-5):257-265
【22】中医病证诊断疗效标准[M]/国家中医药管理局主编.-南京：南京大学出版社,1994：64
【23】中医外科学[M]/李曰庆主编.-北京：中国中医药出版社,2007：145
[24]Barboriak DP,Padua AO,York GE.et al.Creation of DICOM-aware applications using image-J [J]. J Digit Imaging,2005,18 (2):91-99
【25】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社, 1997.8：18,31-32
【26】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：60
【27】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：388
【28】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：391
【29】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：392
[30】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：284
【31】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：166
【32】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：284
【33】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：389
【34】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：479
【35】外科发挥[M]/薛己.-北京：人民卫生出版社,2006：7
【36】中医外科伤科名著集成[M]／胡晓峰主编.-北京：华夏出版社,1997.8：764
【37】黄帝内经素问白话解[M]/王宏图主编.-北京：人民卫生出版社,2004：58
【38】黄帝内经素问白话解[M]/王宏图主编.-北京：人民卫生出版社,2004：69
【39】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：374
【40】中医外科临症精要[M]/罗禹田,艾儒棣,宋根信主编.-成都：四川科技出版社.2007：59
【41】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：7
【42】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：90
【43】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：93
【44】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：168
【45】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：369
【46】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：284
【47】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：763
【48】苏安平,张晓刚.皮肤损伤的中医药治疗机理[J].中医药学刊.2005,.23(.9)：1646～1647
【49】李斌,王一飞.慢性难愈性皮肤溃疡中医药干预策略及若干理论问题探讨[J].中医杂志2011(12)23：2002
【50】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：60
【51】杨毅.姜兆俊.治疗慢性皮肤溃疡的经验[J].江苏中医,2000,21(4)：5
【52】苑相爱,刘洪涛.自制祛腐生肌散在慢性皮肤溃疡治疗中的应用[J].山东医药2010(50)30：82,83
【53】王殿荣.生肌膏配祛腐散治疗骨外露创面不愈口[J].辽宁中医杂志,2006,33(6)：693
【54】苏晓明.七星丹合皮粘散治疗臁疮17例[J].河南中医.2012(32)1：77
【55】常文青,李忠鹏,赵冬雨.祛腐生肌散治疗糖尿病溃疡120例临床观察[J].武警医学院学报,2005,14(1)：48
【56】龙雪.复方黄马酊治疗褥疮17例[J].中医外治杂志.2001,10(5)：44
【57】徐晓文,黄耀.外用中药治疗下肢顽固性皮肤溃疡的临床观察[J].现代中西医结合杂志,2004,13(11)：1452
【58】吕培文,张苍,宋孝瑜等.朱红膏治疗慢性溃疡的临床研究[J].中国中西医结合外科杂志,2003,9(5)：364
【59】刘敏,杜启明,朱学英.雄冰汤治疗小腿溃疡60例[J].中医外治 杂志,2002,11(2)：21
[60】中医外科伤科名著集成[M]／胡晓峰主编.-北京：华夏出版社,1997.8：59
【61】王振宜,李斌,章云.唐汉钩教授运用祛瘀生肌法治疗慢性溃疡经验拾零[J].新中医,2002,34(6)：13
【62】赵翠芬,石玉兰等.乳没生肌散治疗创面久不愈合72例[J].新中医,2007,39(3)：61
【63】陈锋,叶丹,豆哲敏.康复新液联合复合溶菌酶杀菌纱布治疗体表慢性溃疡创面疗效观察[J].现代中西医结合杂志.2011,20(28)：3564
【64】邹连琦,时俊华,刘桂东.活血生新膏促进难愈性皮肤溃疡创面愈合临床观察[J].云南中医中药杂志.2011,32(5)：34-35
【65】王海,丁杰.生肌散治疗伤口经久不愈的临床应用研究[J].辽宁中医药大学学报,2007,9(1)：94
【66】王交莉,张慧.中药外敷治疗放射性皮肤溃疡100例[J].实用中医药杂志2011,(27)4：255
【67】姜礼.生肌玉红膏治疗皮肤疮疡118例[J].中国中医药科技,2004,11(1)：59
【68】蒋萍.中药散治疗慢性溃疡128例临床观察[J].菏泽医专学报,2000,12(4)：67
【69】龚旭初,吴娓星,李虹等.“去腐生新膏”治疗慢性皮肤溃疡临床与实验研究[J].江苏中医药.2006,27(1)：23
【70】张健.祛腐生肌法治疗褥疮75例[J].天津中医药,2003,20(4)：18
【71】褚青波,牛银萍.中药封闭湿敷疗法治疗糖尿病足溃疡体会[J].中医外治杂志.2001,10(5)：44
【72】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：284
【73】刘学清,曾抗,兰海梅等.荆芥连翘汤浸泡治疗慢性下肢溃疡26例疗效观察[J].江西中医药,2006,2(37)：278
【74】兰海梅,陈宝田,杨柳等.荆芥连翘汤体外抑菌实验[J].中华实用中西医杂志,2004,4(23)：1891
【75】马望琪.中药浸泡治疗感染创面36例[J].陕西中医,2003,24(4)：324
【76】张玉镇.中药外洗方治疗郁积性皮炎/溃疡78例[J].中医外科杂志,2011,6(21)：29
【77】侯树德,侯永吉,侯宁静等.生肌玉红膏加生皮散治疗皮肤溃疡121例[J].中医外治杂志,2009,18(4)：12
【78】李杰辉,张力,唐乾利.湿润烧伤膏治疗神经性溃疡临床疗效观察[J].辽宁中医杂志,2012,39(6)：1095-1096
【79】张伟,张宏,张玉杰.湿润烧伤膏结合中药熏洗治疗下肢静脉瘀血性溃疡的效果[J].齐鲁医学杂志,2008,12(23)：545
【80】李红林,王平.外用溃疡散与湿润烧伤膏治疗皮肤溃疡的疗效分析[J]内蒙古中医药,2012,5(8)：29
【81】陈彩霞,王凤轩.紫草生肌膏治疗慢性皮肤溃疡40例[J].中医 外治杂志,2010,20(6)：47
【82】徐杰男,阙华发,唐汉钧.外科煨脓长肉湿润法结合中药内服治疗慢性下肢溃疡132例临床观察[J].上海中医药大学学报,2011,24(6)：47
【83】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：97
【84】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社1997.8：84
【85】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：373
【86】中医外科伤科名著集成[M]/胡晓峰主编.-北京：华夏出版社,1997.8：169
【87】宋军.浅谈慢性皮肤溃疡的辨证治疗[J].湖北中医杂志,2005,27(9)：26
【88】林荔云.自制生肌长皮膏治疗不易愈合创面43例[J].江西中医杂志.2009,12(7)：60
【89】邱庆军,陈力平,林弘.鸡血藤复方对深度慢性溃疡治疗作用的临床疗效分析[J].中国医药导报.2008,5(24):205-206
[90]Smith PD, Kuhn MA, Franz MG, et al. Initiating the inflame-matory phase of incisional healing prior to tissue injury[J]. J Surg Res,2000,92:11
【91】丁韧,汤雪明.创伤愈合的细胞生物学研究进展[J].创伤外科杂 志.2000,2.1：59
[92]LawrenceW.Physiology of the acute wound[J].Clin Plast Surg,1998,25:321-340
[93]SingerA, ClarkRA.Cutaneous wound healing[J]. The New England Journal of Medicine,1999,341:738-746
[94]Stadelmann WK, Digenis AG,Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds[J]. Am J Surg, 1998,176:26S-38S
[95]Lawrence WT. Physiology of the acute wound[J]. Clin Plast Surg,1998,25:321-340
[96]Singer AJ, Clark RA. Cutaneous wound healing[J]. The New England Journal of Medicine,1999,341:738-746
【97】付小兵.进一步重视体表慢性难愈合创面发生机制与防治研究[J].中华创伤杂志,2004,8：450～451
[98]LawreneeWC.Thereversal of a adriaxnyeim induced healing impairmeni with chemo attaetantsand growth factor [J]. Ann-Surg,1991,203:142
【99】李福伦,邓辉,李建伟.慢性难愈性皮肤溃疡B-catenin, c-myc,K6蛋白的表达及意义[J].中国皮肤性病学杂志.2012,24(12)：1093～1094
[100]Sechmid P, Cox DA, Bilbe G, et al.TGF-β and TGF receptor in human epidermis:Differeniial expression in chronic skin wounds[J].J pathol.1993:171:191-197
[101]何仁亮,李红毅,张旖丽.312例下肢创伤性皮肤溃疡创面真菌感染情况分析[J]中国真菌学杂志.2011,10(6)：293-294
[102]YANGYinhui, JIA Chiyu, Geroge W Cherry, et al.Long-term mortality of ultrasound structure in patients with venous leg ulcers healed from one week to twenty years[J]. Chinese Medical Journal.2002;115(12):1819-1823
[103]叶大林等.美宝湿润烧伤膏治疗慢性皮肤溃疡35例报告[J].西南国防医药,2006,16(4)：368
[104]韦佳琛.前列地尔联合重组人表皮生长因子治疗糖尿病性皮肤溃疡疗效观察[J]中国美容医学,2012,21(8)：230
[105]王晓梅,王府,杨晓辉,金成吉,李湘.原位定型微囊化载体制剂在糖尿病大鼠皮肤溃疡中的作用[J].中国组织工程研究与临床康复,2011,15(38)：7123～7126
[106】胡德林,方林森,汪昌荣.重组人表皮细胞生长因子对烧伤后慢性溃疡创面愈合的影响[J]中国现代医学杂志2004,7(13)：20
[107】高梁昌,徐庆华,李岳峰.3种光疗法治疗慢性溃疡[J].中华物理医学与康复杂志,2005,27(7)：446
[108]刘力,李佳怡,熊霞等.改性甲壳素创面修复凝露联合红光照射治疗慢性皮肤溃疡的疗效观察[J]重庆医学,2012,41(33)：3517
[109]原锦,刘钢.皮肤顽固性溃疡微波热疗68例的体会[J].东南国防医药2006,8(3)：197
[110】王昌建,姚元章.负压封闭引流治疗肢体远端慢性感染及溃疡 创面[J].创伤外科杂志2005,7(4)：306
【111】曹大勇等.封闭式负压引流技术对人慢性创面血管生成的影响[J].中国临床康复,2004,8(2)264-265
[112]Shi CM, Cheng TM, Su YP, et al. Transplantation of der-mal multipotent cells promotes the hematopoietic recovery in s-ublethally irradiated rats[J]. J Radiat Res (Tokyo),2004,45:19-24
[113]Gho CG, Braun JE, Tilli CM, et al. Human follicular stem cells:their presence in plucked hair and follicular cell culture[J]. Br J Dermatol,2004,150:860-868
【114]张兆清,余春艳,金岩.复合骨髓间充质干细胞的组织工程皮肤治疗慢性难愈性溃疡探讨[J].中国皮肤性病学杂志.2006,20(4)：211
[115]Stroschein SL,Wang W.Luo K.Cooperative binding of smad proteins to two adjacent DNA elements in the plasminogen aclivator inhibitor 1 promoter mediates transforming rrowth factor beta induced smad dependent transcriptional activation [J]J Biol Chem,1999,274(14):9431-9441
[116]Derynck R.Akhurst RJ,Balmain A.TGF-beta signaling in tumor supression and cancer progression[J].Nature Genet, 2001,29(2):117-129
【117】丁韧汤,雪明.创伤愈合的细胞生物学研究进展[J].创伤外科杂 志2000,2(1)：60
[118]Kishi K,Nakajima H,Tajima S.Differential responses of collagen anglycosaminoglycan syntheses and cell proliferation to exogenous transforming growth factor beta-1 in the developing mouse skin fibroblasts iculture[J].Br J Plast Surg, 1999,52(7):579-582
[119]Le-PoolelC, Boyce ST.Keratinocytes suppress transform-ing growth factor-beta, expression by fibroblasts incultured sk-in substitutes [J].BrDermatol,1999,140(3):409-416
[120]Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secr-ete a vascular permeability factor that promotes accumulation of ascites fluid[J]. Science,1983,219(4587):983-985
[121】蔡源源.VEGF的调控及其作用研究进展[J].组织工程与重建外科杂志.2011,7(1)：51～53
[122]Jakeman LB,Winer J,Bennett GL.et al.Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissue[J].J Clin Invest,1992,89:244
[123]Brown LF,Yeo KT,Berse B,et al.Expression of vascular permeability factor (Vascular Endothelial Growth Factor) by epidermal kerationcytes during wound healing[J].J Exp Med, 1992,176:1375
[124]Pepper MS,Ferrara N,Orci L,et al.Vascular endothelial growth factor(VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells[J].Biochem Biophys Res Commun,1991,181:902
[125]Campbell B.Chuhran C, Lefer AM.Vascular endothelial growth factor attenuates trauma-induced injury in rats[J].Br Ph-armacol.2000,129:71-76
[126]Ghosh AK, Yuan W, Mori Y, et al.Smad-dependent stim-ulation of type I collagen gene expression in human skin fibrobl-asts by TGF-beta involves functional cooperation with p300/ CBP transcriptional coactivators[J].Oncogene,2000,19(31): 3546-3555
【127】丁杰,付贵峰.细胞因子与创伤愈合的关系[J].安徽医学.2005.26(6)：552
[128]Chose k. Gu L,Zhu YJ,YangX,et al.Effect of TGF-beta/S-mad signaling pathway on lung myofibroblast differentiation[J]. Acta Pharmacol Sin.2007;28(3):382-391
[129]Rhett JM, Ghatnekar GS, Palatinus JA, etal.Novel therapies for scar reduction and regenerative healing of skin wounds[J]. Trends biotechnol.2008;26(4):173-180
[130]Jagadeesan J.Bayat A.Transforming growth factor beta (TGF-beta) and keloiddisease[J].Int J Surg.2007;5(4):278-285
[131]Hu B,WuZ,Phan SH.Smad3 mediates transforming grow- th factor-beta Induced alphasmooth muscleactinexpression[J]. Am J Respir Cell Mol Biol.2003:29(3 Pt 1):397-404
[132]Reynolds A,Leake D,Boese Q,et al.Rational siRNA design for RNA Interference[J]. Nature Biotechnology.2004:22:326-330
[133]Zheng R, Xiong Q, Zuo B, et al.Using RNA interference to identify the different roles of SMAD2 and SMAD3 in NIH/3T3 fibroblast cells[J].Cell Biochem Funct.2008;26(5):548-556
[134]Gao Z, Wang Z, Shi Y, et al.Modulation of collagen syn-thesis in Keloid fibroblasts by silencing Smad2 withsiRNA[J].PI-ast Reconstr Surg.2006;118(6):1328-1337
【135】王爱丽,吴志宏,徐顺等.Smad3基因siRNA表达载体的构建及沉默效应[J].中国组织工程研究与临床康复.2011,15(28)5285-5288
【136】神农本草经[M]/清·黄爽辑.北京：中医古籍出版社,1982：238
【137】新修本草[M]/唐·苏敬.合肥：安徽科技出版社,1981：416
【138】重修政和经史证类备用本草[M]/宋·唐慎微.北京：人民卫生出版社,1982：433-434
【139】本草纲目[M]/明·李时珍.北京：人民卫生出版社,1985：2325
【140】本草纲目拾遗[M]/清·赵学敏.北京：人民卫生出版社影印,1957：373
【141】本草纲目拾遗[M]/清·赵学敏.北京：人民卫生出版社影印, 1957：373
【142】中药大辞典[M]／江苏中医学院主编.上海：上海人民出版社,2008：492
【143】全国中草药汇编[M]／《全国中草药汇编》编写组主编.北京：人民卫生出版社,1978：699
【144】中哈尼族医药[M]／何建疆,黄晴岚主编.昆明：云南民族出版社,1999：350
【145】姚廉.中药蜚蠊化学成分的研究.氨基酸成分的初步分析[J]天津药学,1994,6(3)：26-28.
[146]Brown B E, StarrattA N, Isolation of p roctolin, amyotropic peptide rom Periplaneta americana [J].J Insect Physiol,1975,2 1:1879
【147】何正春,彭芳,宋丽艳等.大蠊化学成分及药理作用研究进展[J].中药杂志,2007,32(21)：2326-2331
【148】吴仕筠,代小艳,米长忠.蜚蠊药用的研究的研究[J].中国民族民间医药.2008,8(6)：7
【149】中药大辞典[M]／江苏新医学院主编.上海：上海人民出版社,2008：146
【150】全国中草药汇编[M]／《全国中草药汇编》编写组主编.北京：人民卫生出版社,1978：699
【151】中国哈尼族医药[M]／何建疆,黄晴岚主编.昆明：云南民族出版社,1999：350
【152】云南药品标准[M]/云南省卫生厅主编.昆明：云南大学出版社,1998：123～124
【153】云南省中药材标准[M]/云南省食品药品监督管理局主编.昆明：云南美术出版社,2005：54
【154】高顺,高孟婷,马芳芳.美洲大蠊药理作用及临床应用研究进展[J].安徽农业科学.2012,40(10)：5933-5935,5942
【155】郑远达,闻强,季永领,康复新液防治放疗患者口腔黏膜急性放射损伤的观察[J].华西药学杂志,2006,21(4)：404
【156】陈晓红,程天民,冉新泽.电离辐射对大鼠伤口中性粒细胞肌动蛋白的影响[J].中华放射医学与防护杂志,2000,20(6)388-390
【157】陈新,王洪,张艳萍.康复新液的最新临床应用[J].中国医学指南,2008,9(17)：89～94
【158】焦春香,刘光明,周萍.天然药物康复新的研究进展[J].时珍国医国药.2008,19(11)：2623
【159】胡根云,周伟琴,钟丽红.维生素E胶丸外涂加康复新液外敷治疗褥疮疗效观察[J].现代中西医结合杂志,2007,16(25)：3635
【160】洪砌.康复新液治疗溃疡性结肠炎22例临床观察[J].医学理论与实践,2003,16(9)：1044
【161】尚政军,李金荣.修复相关基因Smad3的研究进展[J].国外医学分子生物学分册.2001,23(5)：278,279
【162】舒崇湘,程天民,阎国和等.6-Gy全身照射对皮肤伤口几种细胞外基质成分的影响及W11-a12的促愈作用[J].中华创伤杂志,2001, 11(10)：604
【163】舒崇湘,程天民.康复新对单纯皮肤创面和合并全身放射损伤时的促愈作用[J].第三军医大学学报,1999,21：164
【164】舒崇湘,叶奉兰,程天民,等.电离辐射对小鼠腹腔巨噬细胞阴离子通道活动的影响及康复新对其的作用[J].第三军医大学学报,2001,23(3)：290
【165】李珊瑚,李勇敏,彭淑珍,康复新液对家兔创伤愈合的影响[J].临床和实验医学杂志,2006,5(6)：730
【166】陈晓红,程天民,艾国平.电离辐射对伤口_中性粒细胞的影响及康复新的促愈作用[J].第三军医大学学报,2001,23(3)：287
【167】范湘玲,王文英,张兵.康复新液配合微波治疗宫颈糜烂临床观察[J].中国中医药信息杂志,2006,13(1)：65～66
【168】陈晓红,程天民,艾国平.电离辐射伤口中性粒细胞的影响及康复新的促俞作用[J].第三军医大学学报,2001,23(3)：287-289
【169】舒崇湘,叶本兰,程天民等.电离辐射对小鼠腹腔巨噬细胞阴离子通道活动的影响及康复新对其的作用[J].第三军医大学学报,2001,23(3)：290-292
【170】席小燕,易红梅,池晓红等.“康复新液’’治疗褥疮30例的临床观察[J].四川医学,2004,25(2)：249
【171】叶本兰,舒崇湘,程天民等.电离辐射对3T3细胞膜钙依赖性钾通道的影响及康复新的作用[J].中国应用生理学杂志,2002,3：290